It is worth mentioning that MK1775 showed the gastrointestinal reaction side‐effect in its clinical trials treating cancers.[31] Therefore, it is suggested to develop new small‐molecule inhibitors targeting the interaction between WEE1 and p65 to treat atherosclerosis, which may avoid the side effects of the classic anti‐cancer inhibitors of WEE1 kinase. This evidence concerns the gene RELA and atherosclerosis.